Clinical Endocrinology (2006) 64, 423–428 Effects of growth reduction therapy using high-dose 17β-estradiol in 26 constitutionally tall girls
U. Radivojevic, E. Thibaud, D. Samara-Boustani, C. Duflos and M. Polak
Department of Paediatric Endocrinology and Gynaecology, Necker-Enfants Malades Hospital, Paris, France Introduction
The use of sex steroids to reduce final height in patients with con-
Objective The efficacy and safety of height-limiting therapy with
stitutionally tall stature (CTS) remains controversial. CTS is defined
high-dose 17β-oestradiol in girls with constitutionally tall stature
as an SD of at least 2 above the mean height for sex and chronological
(CTS) are controversial. We evaluated the effectiveness of high-dose
age in a relevant reference population,1 after exclusion of overgrowth
17β-oestradiol in premenarchal girls with CTS treated until their
syndromes.1–3 Although CTS is related primarily to familial factors,
nutrition,1,2 hormonal status and socioeconomic environment also
Design We retrospectively reviewed the medical records of the girls
managed between 1989 and 2000 with high-dose 17β-estradiol for
The diagnosis usually rests on a family history of tall stature and on
CTS with a predicted final height greater than +3SDs.
physical findings distinguishing CTS from overgrowth syndromes.1–3
Patients Twenty-six girls met our inclusion criteria. At baseline, mean
Evaluation of the tall girl should include a medical history, physical
chronological age was 12·06 ± 1·51 years and mean height was 171·1
examination, estimation of growth potential and a battery of labor-
± 6·5 cm with a height standard deviation score of 4·5 ± 0·24, and mean
predicted final height was 183·0 ± 4·2 cm. Treatment was stopped
Bone growth and maturation result from a complex interplay of
when bone age reached 14 years; mean treatment duration was
multiple hormones and growth factors.1,4 At puberty, sex steroids,
predominantly oestrogens in girls (in combination with other hormones
Measurements The following were obtained at 6-month intervals:
and growth factors), induce an increase in growth velocity followed
height, body weight, Tanner stage, bone age, plasma cholesterol and
by closure of the epiphyseal growth plates with cessation of linear
triglycerides, plasma glucose and side effects. A mailed questionnaire
growth in long bones.4 High-dose oestrogens may accelerate growth plate
on final height and satisfaction was sent 2 years after treatment dis-
closure without increasing growth velocity, thus reducing the final height
continuation (response rate, 24/26).
compared to the predicted final height.1,5 Selecting patients for high-
Results Final height was significantly (P < 0·001) reduced, by
dose oestrogen therapy depends on an accurate estimation of final
2·4 ± 3·2 cm, as compared to predictions. High-dose 17β-estradiol
height: treatment is usually considered only when the predicted final
therapy decreased growth velocity and significantly increased skele-
height exceeds 3 SDs above the mean in the general population.6,7
tal maturation (P < 0·001). Linear growth after treatment discon-
Thus, predicting final height plays a crucial role in the manage-
tinuation was 3·3 ± 1·9 cm. No serious side effects were recorded.
ment of children with CTS.6,8 The most widely used method for pre-
Most of the patients were satisfied with the treatment.
dicting final height, which was devised by Bailey and Pinneau (BP
Conclusion High-dose 17β-estradiol was moderately effective in
method), is well suited to clinical practice but is highly dependent
reducing final height and should probably be reserved for selected
on the ability to obtain an accurate estimation of bone age.9–11 Height
patients, particularly as knowledge on potential long-term side
prediction using the BP method in children with CST has been found
inaccurate in boys but clinically acceptable in girls.6
(Received 9 June 2005; returned for revision 21 July 2005; finally
Numerous publications have confirmed the effectiveness of high-
revised 19 September 2005; accepted 1 December 2005)
dose oestrogen therapy in slowing linear growth in girls. Other studies found that high-dose oestrogens accelerated bonematuration.7,12–14,16–19 To date, the main oestrogens used for growthinhibition have been conjugated oestrogens and ethinyl oestra-diol.12,20,21 Side effects of high-dose oestrogen therapy for growthinhibition have been reported, and the risk/benefit ratio remainsunclear, most notably regarding the risk of cancer22 and thromboem-
Correspondence: E. Thibaud, Department of Paediatric Endocrinology and
bolism.23–25 As compared to conjugated oestrogens or ethinyl oestra-
Gynaecology, Necker-Enfants Malades Hospital, 149,rue de Sèvres, 75743
Paris cedex 15. France. Tel.: +331 44494801; Fax: +331 44494800;
β oestradiol has shown a better metabolic safety profile, with
less weight gain, dyslipidaemia and thromboembolism.26 In this
study, we therefore examined the height-limiting effect and tolerance
of oral 17β estradiol in 26 constitutionally tall girls.
Results are reported as mean (SD) values with the 95% confidenceinterval (95%CI) and standard error (SE). Student’s t-tests were per-
Subjects and methods
formed, and analysis of variance was used to evaluate the influence
Between 1989 and 2000, 26 premenarchal constitutionally tall girls
of variables on treatment effects. P value of < 0·05 were considered
completed 17β-estradiol treatment at the Paediatric Endocrinology
and Gynaecology Department of the Necker-Enfants Malades Teach-ing Hospital, Paris, France. CTS was defined as a height (expressed
as the SD of observed height for age) equal to or greater than 2 SDsat referral, after exclusion of other causes of excessive growth. Treat-
ment was offered to patients who requested height-limiting therapyand whose predicted height was at least 179 cm (+3 SD for the gen-
At baseline, mean chronological age was 12·06 ± 1·51 years and mean
eral population in France).27 Consent of the parents was obtained.
height was 171·1 ± 6·5 cm with a height SDS of 4·5 ± 0·24. Mean
The girls were treated with 4·0–8·0 mg/day of 17β-estradiol, com-
treatment duration was 1·62 ± 0·76 years. Predicted final height
bined with the progestogen chlormadinone acetate, 10 mg/day and
± 4·3 cm, height at treatment discontinuation was
15 days/month to induce cyclic bleeding and to avoid over-stimulation
179·7 ± 3·7 cm and final height was 183·0 ± 4·2 cm. The mean reduc-
of the endometrium. The dose of 8 mg of 17β-estradiol was chosen
tion in final height was 2·4 ± 3·2 cm, which was statistically signifi-
in the majority of patients because of the following bioequivalence:
8 mg is equivalent to 0,10 mg of ethinyl oestradiol and because it has
Throughout treatment, skeletal maturation was accelerated and
been found to be efficacious for height reduction in tall stature.28 The
growth rate was decreased. During the first 6 months of therapy,
treatment was stopped when bone age reached 14 years. This BA was
bone age increased by 1·0 ± 0·33 years, indicating a significant accel-
chosen at the beginning of the study because it meant that that at
eration of bone age (P < 0·001) consistent with 17β-estradiol-
least 98% of growth had been completed. Throughout treatment,
induced stimulation of cartilage maturation. Bone age acceleration
patients were evaluated at 6-month intervals for measurement of
remained significant when the first year of treatment was considered
body weight and height, Tanner stage determination and recording
(Table 3). After treatment discontinuation, height continued to
of side effects. All height measurements were performed using the
increase, with the mean gain being 3·3 ± 1·9 cm. Thus, final
same stadiometer. Radiographs of the left hand and wrist were also
height was significantly higher (P < 0·001) than height at treatment
obtained at each evaluation for bone age assessment, which was per-
discontinuation. However, the final height predicted at treatment
formed by a single experienced physician using the Greulich and Pylemethod.10 Bone age acceleration was calculated based on the boneage increase from baseline to the 6- and 12-month time points. Final
Table 2. Height parameters during and after high-dose 17β-oestradiol therapy in 26 girls with constitutionally tall stature
height was predicted using the tables of Bayley and Pinneau.9 Finalheight reduction was computed as the difference between predicted
height at baseline and observed final height (see succeeding discus-
sions). Plasma levels of cholesterol, triglycerides (n = 10) and glucosewere measured to monitor safety.
All patients were sent a questionnaire by mail at least 2 years after
treatment discontinuation. The questionnaire items included height,
which was therefore used as final height in the study, treatment
Predicted height at end of treatment 183·1 3·3 0·68 181·6–184·5
acceptance, patient satisfaction with the treatment, body weight and
regularity of menstrual cycles. Of the 26 patients, 24 returned com-
Table 1. Baseline clinical features in 26 girls with constitutionally tall stature treated with high-dose 17β-oestradiol Table 3. Bone age and growth rate during high-dose 17β-oestradiol therapy in 26 constitutionally tall girls
*Bone age acceleration was calculated as the difference between baseline bone age and age after 6 and 12 months of therapy, divided by 6 and 12 months,
2006 Blackwell Publishing Ltd, Clinical Endocrinology, 64, 423–428 High-dose 17β-estradiol in tall girls 425 Table 4. Height parameters during and after high-dose 17β-oestradiol therapy in the three patient subsets based on the relationship between bone age and chronological age (overall population, n = 26)
discontinuation was not significantly different from the final heightrecorded at last follow-up.
To evaluate the effect of therapy according to bone maturation at
baseline, we divided the patients into three groups based on whetherbone age at baseline was less than chronological age (BA < CA,n = 10), equal to chronological age (BA = CA, n = 7) or greater thanchronological age (BA > CA, n = 9) (Table 4). The BA < CA grouphad the highest values for mean baseline height (174·5 cm) and finalheight (183·8 cm); post-treatment growth was 3·4 cm and finalheight reduction was 2·4 cm. The BA = CA group had the lowestvalues for mean baseline height (167·2 cm), final height (179·1 cm),post-treatment growth (2·4 cm) and final height reduction was3·0 cm. In the BA > CA group, mean baseline height was intermediatebetween the other two groups (170·4 cm). This group had thehighest values for predicted final height (187·2 cm), final height(184·3 cm) and post-treatment growth (3·6 cm); final height reduc-tion was 2·9 cm. By analysis of variance, none of these differenceswas statistically significant. Thus, the relationship between bone ageand chronological age at baseline had no influence on treatment
Fig. 1 Body mass index (BMI) variations during the first 2 years of 17β-
effects in our cohort of 26 patients.
oestradiol therapy in 26 girls with constitutionally tall stature (values in the upper panel and with percentile according to age in the lower panel).
Overall tolerance was good in our group of patients. No serious side
The questionnaires showed that 19 of the 24 respondents were
effects were noted. Five girls had one or more of the following:
satisfied with the treatment, that three wished they had not received
fatigue, nausea, breast discomfort, abdominal pain and triglyceride
it, and that two were neither satisfied nor dissatisfied. Greater post-
elevation. However, breast discomfort was reported by a single
treatment growth was noted in patients who were dissatisfied.
patient, suggesting that high-dose 17β-estradiol therapy may havelittle influence on breast development. Discussion
Glucose metabolism was normal in all patients. Of the 10 patients
who underwent triglyceride assays, only one had triglyceride eleva-
Our data suggest that high-dose 17β-estradiol was effective in reduc-
tion during therapy with a return to normal after treatment
ing final height when started in premenarchal girls with CST. The
discontinuation. No blood pressure changes were found, and no
mean reduction in final height was 2·4 ± 3·2 cm, in keeping with
thromboembolic events were recorded. Body mass index during
earlier studies reporting corrected and uncorrected reductions in the
treatment did not vary significantly (Fig. 1). Spontaneous cyclical
2·1–10·0 cm range.6,12,19,29 The mean age and bone age were rather
bleeding occurred in 24 patients within 6 months and in two patients
advanced at start of treatment, a factor that may have contributed
within 11 months after treatment discontinuation. These data
to the modest result. Furthermore, the result was less marked than
suggest that side effects were mild during treatment, although the
expected because treatment was stopped at a bone age of 14 years
small sample size and short follow-up should be borne in mind. No
which, a posteriori, was too early. Finally we used self-reported
side effects were reported after treatment discontinuation.
height, which has been shown to be well correlated with measured
2006 Blackwell Publishing Ltd, Clinical Endocrinology, 64, 423–428
height.30,31 There is even a tendency in these studies to increase self-
Furthermore, we did not evaluate potential long-term side effects.
reported heights. In our study this would have reduced the apparent
The current uncertainty regarding the risk/benefit ratio of high-
beneficial effect of the height reduction therapy. However, com-
dose oestrogen height-limiting therapy should be borne in mind. In
parisons are hampered by differences across studies regarding base-
particular, whether oestrogen height-limiting therapy increases the
line clinical features (most notably chronological age and bone age),
risk of cancer of the breast or other sites remains unclear. In our
treatment duration, therapeutic regimen (dose and nature of the
study, a single patient reported breast discomfort, and no clinically
oestrogen preparations) and the time of final height assessment.28,32,33
significant breast disease was observed. This finding is in agreement
Skeletal maturation was significantly accelerated throughout the
with earlier studies.1 However, long-term data on the breast cancer
first treatment year in our study, and growth velocity decreased
risk after high-dose 17β-oestradiol height-limiting treatment are not
concomitantly. These data are consistent with in vitro evidence
that high-dose oestrogens stimulate cartilage maturation without
We consider that the benefits from high-dose 17β-estradiol
increasing growth velocity and that oestrogens accentuate the age-
therapy in terms of height reduction were moderate. Furthermore,
related decrease in chondrocyte size.34,35
although high-dose 17β-estradiol seems safe in the short term,
Mean post-treatment growth was 3·3 ± 1·9 cm in our study, in
harmful long-term effects cannot be excluded. Nevertheless, 17β-
agreement with previous data.6,11,19,23 The cause of post-treatment
estradiol therapy may deserve consideration in girls with a very tall
growth is unclear. Mean bone age at treatment discontinuation in
predicted final height, no family history of breast cancer and no
our study was 14 years. Conceivably, treatment was stopped before
family or personal history of dyslipidaemia or coagulopathy.
complete epiphyseal closure, allowing for subsequent growth. Alter-
New approaches to the pharmacological treatment of CTS in girls
natively, late pubertal completion of spinal growth may lead to an
are needed. Drugs that influence GH secretion, such as the somato-
additional gain in stature after treatment discontinuation.6
statin analogues octapeptide and lanreotide, have been widely used
The marked interindividual variability in final height reduction
to treat acromegaly for the last decade and have also been evaluated
suggests that a subgroup of patients may derive greater benefit from
in CTS.43,44 The GH receptor antagonist pegvisomant is being devel-
treatment than the overall population. Our analysis of subgroups
oped as an agent that antagonizes GH effects without acting on the
defined by the relation between bone age and chronological age at
pituitary gland or inhibiting GH secretion. This agent may prove an
baseline, however, found no statistically significant differences were
attractive alternative to oestrogens for final height reduction.45 How-
found regarding final height, growth reduction or post-treatment
ever, further studies are needed to assess this possibility.
growth. Thus, one or more unknown factors may underlie the inter-
In summary, our study shows that high-dose 17β-estradiol
individual variability in treatment efficacy; variations in oestrogen
treatment is moderately effective in reducing the final height of girls
receptor behaviour may be among these factors.
with CTS. This treatment induces significant skeletal maturation and
No serious side effects were noted. Of 26 patients, 5 experienced
a decrease in growth velocity. The post-treatment growth in our
fatigue, nausea, increased pigmentation, breast discomfort and/or
patients may be ascribable in part to the fact that bone age was only
abdominal pain. All side effects resolved after treatment discontinu-
14 years at 17β-estradiol discontinuation. No serious side effects
ation, and no thromboembolic events occurred. These findings
were noticed. Most of the patients were satisfied with the treatment.
support published data. High-dose ethinyl oestradiol or conjugated
Nevertheless, the moderate treatment effect and the continuing
oestrogen therapy have been reported to cause adverse effects, most
uncertainty about the long-term safety of high-dose 17β-estradiol
of which were mild and reversible. The adverse event rate may be
therapy indicate a need for caution. Research is needed to develop
dose-dependent.20,33 Serious adverse events such as thromboembo-
lism seem exceedingly rare.36 Triglyceride elevation occurred in one ofour patients but resolved after treatment discontinuation. Similarly,
in earlier studies,37,38 lipid changes proved reversible after treatmentdiscontinuation. There was no evidence up to 2004 that high-dose
U.R. was supported by a grant from ‘Groupement Français de Gyné-
oestrogen therapy causes long-term alterations in reproductive
cologie de l’Enfance et de l’Adolescence’.
function.1,39 A recent retrospective study of a large cohort of treatedgirls indicate an association with slightly impaired fertility in later
life: treated women took longer to conceive and more requiredfertility services.40 Spontaneous cyclical bleeding occurred in all but
1 Drop, S.L.S., De Wall, W. & De Munick Keizer-Schrama, S. (1998)
two patients within 6 months of treatment discontinuation. Others
Sex steroid treatment constitutionally tall stature. Endocrine Reviews,
reported menarche within 1–6 months after the end of treatment,
19 (5), 540 –558.
usually within the first month.41 In our study, two patients were
2 Preece, M.A. (1996) The genetic contribution to stature. Hormone
amenorrohoeic for 11 months after the treatment was stopped. Post-
Research, 45, 56 –58.
3 Root, A.W. (2001) The tall, rapidly growing infant, child and
treatment amenorrhea lasting longer than 6 months after cessation
adolescent. Current Opinions in Endocrinology and Diabetes, 8, 6–
of height-limiting oestrogen therapy occurred in about 5% of
4 Turner, R.T., Riggs, B.L. & Spelsberg, T.C. (1994) Skeletal effects of
No studies specifically designed to evaluate the side effects of
estrogen. Endocrine Reviews, 15, 275 –300.
high-dose 17β-estradiol therapy have been reported. Our sample
5 Gustafsson, P.O., Kasstrom, H., Lindberg, L. & Olsson, S.E. (1975)
size is too small to allow definitive conclusions regarding safety.
Growth and mitotic rate of the proximal tibial epiphyseal plate in
2006 Blackwell Publishing Ltd, Clinical Endocrinology, 64, 423–428 High-dose 17β-estradiol in tall girls 427
hypophysectomized rats given estradiol and human growth hormone.
26 Scarabin, P.Y., Oger, E. & Plu-Bureau, G. (2003) Differential associ-
Acta Radiologica Supplement, 344, 69 –74.
ation of oral and transdermal oestrogen-replacement therapy with
6 De Waal, W.J., Greyn-Fokker, M.H., Stijnen, T., Van Gurp, E.A.,
venous thromboembolism. Lancet, 362, 428 –432.
Toolens, A.M., De Muinck Keizer-Schrama, S.M.P.F., Aarsen, R.S.R. &
27 Sempé, M., Pedron, G. & Roy-Pernot, M.P. (1979) Auxologie,
Drop, S.L.S. (1996) Accuracy of final height prediction and effect of
méthode et séquences. Paris, Théraplix.
growth-reductive therapy in 362 constitutionally tall children.
28 Ignatius, A., Lenko, H.L. & Perheentupa, J. (1991) Oestrogen treat-
Journal of Clinical Endocrinology and Metabolism, 81, 1206 –1121.
ment of tall girls: effect decreases with age. Acta Paediatrica Scandi-
7 Binder, G., Grauer, M.L., Wehner, A.V., Wehner, F. & Ranke, M.B. navica, 80, 712–717.
(1997) Outcome in tall stature: final height and psychological aspects
29 Svan, H., Ritzén, E.M., Hall, K. & Johansson, L. (1991) Estrogen
in 220 patients with and without treatment. European Journal of
treatment of tall girls: dose dependency of effects on subsequent
Pediatrics, 156, 905 –910.
growth and IGF-I levels in blood. Acta Paediatrica Scandinavica, 80,
8 De Waal, W.J., Stijnen, T., Lucas, I.S., van Gurp, E., de Muinck Keiser-
Schrama, S. & Drop, S.L. (1996) A new model to predict final height
30 Brener, N.D., McManus, T., Galuska, D.A., Lowry, R. & Wechsler, H.
in constitutionally tall children. Acta Pediatrica, 85, 889– 893.
(2003) Reliability and validity of self-reported height and weight
9 Bayley, N. & Pinneau, S. (1952) Tables for predicting adult height
among high school students. Journal of Adolescent Health, 32, 281–
from skeletal age: revised for use with the Greulich-Pyle hand stand-
ards. Journal of Pediatrics, 40, 423 – 441.
31 Wada, K., Tamakoshi, K., Tsunekawa, T., Otsuka, R., Murata, C.,
10 Greulich, W.W. & Pyle, S.I. (1959) Radiographic Atlas of Skeletal
Nagasawa, N., Matsushita, K., Sugiura, K., Yatsuya, H. & Toyoshima,
Development of the Hand and Wrist 2nd edn. Stanford University
H. (2005) Validity of self-reported height and weight in a Japanese
workplace population. International Journal of Obesity, 29, 1093 –
11 Preece, M.A. (1988) Prediction of adult height: methods and problems. Acta Paediatrica Scandinavica Supplement, 347, 4 –11.
32 Joss, E.E., Zeuner, J., Zurbrügg, R.P. & Mullis, P.E. (1994) Impact of
12 Zachmann, M., Ferrandez, A., Mürset, G. & Prader, A. (1975)
different doses of ethinyl estradiol on reduction of final height in
Estrogen treatment of excessively tall girls. Helvetica Paediatrica Acta,
constitutionally tall girls. European Journal of Pediatrics, 153, 797– 30, 11–30.
13 Reeser, H.M., Heremans, G.F. & van Gelderen, H.H. (1979)
33 Breur, G.J., VanEnkevort, B.A., Farnum, C.E. & Wilsman, N.J. (1991)
Reduction of adult height in tall girls. European Journal of Pediatrics,
Linear relationship between the volume of hypertrophic chondro-
cytes and the rate of longitudinal bone growth in growth plates.
14 Bierich, J.R. (1978) Estrogen treatment of girls with constitutional
Journal of Orthopaedic Research, 9, 348 –359.
tall stature. Pediatrics, 62, 1196 –1201.
34 Strickland, A.L. & Sprinz, H. (1973) Studies of the influence of estra-
15 Weinmann, E., Bergmann, S. & Bohles, H.J. (1998) Oestrogen
diol and growth hormone on the hypophysectomized immature rat
treatment of constitutional tall stature: a risk–benefit ratio. Archives
epiphyseal cartilage growth plate. American Journal of Obstetrics andof Disease in Childhood, 78, 148 –151. Gynecology, 115, 471– 477.
16 Kuhn, N., Blunck, W., Stahnke, N., Wiebel, J. & Willig, R.P. (1977)
35 Wettenhall, H.N.B., Cahill, C. & Roche, A.F. (1975) Tall girls: a survey
Estrogen treatment in tall girls. Acta Paediatrica Scandinavica, 66,
of 15 years of management and treatment. Journal of Pediatrics, 86,
17 Colle, M.L., Alperin, H. & Greenblatt, R.B. (1977) The tall girl:
36 Muntean, W. & Borkenstein, M. (1980) Haemostatic changes in tall
prediction of mature height and management. Archives of Disease in
girls treated with high doses of ethinyl oestradiol. European JournalChildhood, 52, 118–120. of Pediatrics, 134, 245 –248.
18 Grüters, A., Heidemann, P., Schlüter, H., Stubbe, P., Weber, B. &
37 Hinkel, G.K., Hanefeld, M., Jaross, W., Leonardt, W. & Trubsbach,
Helge, H. (1989) Effect of different oestrogen doses on final height
A. (1985) Effect of high doses of estrogens and androgens on lipo-
reduction in girls with constitutional tall stature. European Journal
proteins: observations in the treatment of excessive growth with
of Pediatrics, 149, 11–13.
sexual hormones. Experimental Clinical Endocrinology, 86, 1 7 –25.
19 Normann, E.K., Trygstad, O., Larsen, S. & Dahl-Jørgensen, K. (1991)
38 Weninger, M., Frisch, H., Schober, E., Strobl, W. & Widhalm, K.
Height reduction in 539 tall girls treated with three different dosages
(1987) Increase of serum lipids and serum lipoproteins in girls under
of ethinyloestradiol. Archives of Diseases in Childhood, 66, 1275–
therapy with estrogen and norethisterone for height reduction. ActaPaediatrica Scandinavica, 76, 500 –503.
20 Bartsch, O., Weschke, B. & Weber, B. (1988) Oestrogen treatment of
39 Hanker, J.P., Schellong, G. & Schneider, H.P.G. (1979) The functional
constitutionally tall girls with 0·1 mg/day ethinyl estradiol. European
state of the hypothalamo-pituitary axis after high-dose oestrogen
Journal of Pediatrics, 147, 59 –63.
therapy in excessively tall girls. Acta Endocrinologica, 91, 19 –29.
21 Bailey, J.D., Park, E. & Cowell, C. (1981) Estrogen treatment of girls
40 Venn, A., Werther, G., Pyett, P., Baird, D., Jones, P., Rayner, J. &
with constitutional tall stature. Pediatric Clinics of North America, 28,
Lumley, J. (2004) Oestrogen treatment to reduce the adult height
of tall girls: long-term effects on fertility. Lancet, 364, 1513–
22 Hamilton, A.S. & Thomas, M.M. (2003) Puberty and genetic
susceptibility to breast cancer in a case-control study in twins. New
41 Andersen, H., Jacobsen, B.B., Kastrup, K.W., Krabbe, S., Peitersen, B.,
England Journal of Medicine, 348, 2313 –2322.
Petersen, K.E., Thamdrup, E. & Wichmann, R. (1980) Treatment of
23 Werder, E.A., Waibel, P., Sege, D. & Flury, R. (1990) Severe throm-
girls with excessive height prediction: follow-up of forty girls treated
bosis during oestrogen treatment for tall stature. European Journal
with intramuscular estradiol and progesterone. Acta Paediatricaof Pediatrics, 149, 389 –390. Scandinavica, 69, 293 –297.
25 Weimann, E. & Brack, C. (1996) Severe thrombosis during treatment
42 De Waal, W.J., Torn, M., De Muinck Keizer-Schrama, S.M.P.F.,
with ethinyl estradiol for tall stature. Hormone Research, 45, 261–263.
Aarsen, R.S.R. & Drop, S.L.S. (1995) Long-term sequelae of sex
2006 Blackwell Publishing Ltd, Clinical Endocrinology, 64, 423–428
steroid treatment in the management of constitutionally tall stature.
44 Tauber, M.T., Harris, A.G. & Rochiccioli, P. (1994) Clinical use of
Archives of Disease in Childhood, 73, 311–315.
long-acting somatostatin analogue octreotide in pediatrics. Euro-
43 Hindmarch, P.C., Pringle, P.J., Stanhope, R. & Brook, C.G. (1995)
pean Journal of Pediatrics, 153, 304 –310.
The effect of a continuous infusion of a somatostatin analogue
45 Parkinson, C., Scarlett, J.A. & Trainer, P.J. (2003) Pegvisomant in the
(octreotide) for 2 years on growth hormone secretion and height
treatment of acromegaly. Advanced Drug Delivery Reviews, 55, 1303 –
prediction in tall children. Clinical Endocrinology, 42, 509 –515.
2006 Blackwell Publishing Ltd, Clinical Endocrinology, 64, 423–428
Technical Information Table 1 lists over 450 chemicals whose corrosive Tefzel ® fluoropolymer resin is a proven performer incharacteristics create problems which can often bethe chemical and petrochemical processing indus-solved by specifying Tefzel ® fluoropolymer. Thetries. It has gained notable recognition for its uniquemaximum use temperature for each chemicalproperties and des
Safety Data Sheet 91/155/EEC(gb) arecal INOX CLEANER Anchorfast Limited 01. Identification of the substance / preparation and of the company Product: arecal INOX CLEANER Article number 0895 112 500 Use: See product designation Company: Anchorfast Limited Doranda WayUK- West Bromwich, West Midlands B71 4LU Phone: 0044-121-5250525 Homepage: Emergency phone: 0044-121-5